Shanghai Henlius Biotech refiles $500m IPO application

Shanghai Henlius Biotech has resubmitted its application to list on the Hong Kong Stock Exchange with an IPO worth around $500m.

  • By Gina Lee
  • 08 Jul 2019

The biotechnology company is being spun off by parent Shanghai Fosun Pharmaceutical Group.

The refiling last Friday came as the initial application filed with the HKEX in December 2018 lapsed. Shanghai Fosun had approved the spin-off at a board meeting three months earlier.

Shanghai ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Panda Bonds Top Arrangers

Rank Arranger Share % by Volume
1 Bank of China (BOC) 21.85
2 China Merchants Securities Co 14.67
3 Industrial and Commercial Bank of China (ICBC) 14.44
4 Agricultural Bank of China (ABC) 8.89
5 China Securities 7.41

Bookrunners of Asia-Pac (ex-Japan) ECM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 CITIC Securities 9,346.38 46 7.88%
2 Goldman Sachs 8,791.68 35 7.42%
3 Morgan Stanley 6,937.95 46 5.85%
4 China International Capital Corp Ltd 6,923.83 42 5.84%
5 UBS 6,281.96 46 5.30%

Bookrunners of Asia Pacific (ex-Japan) G3 DCM

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 HSBC 20,690.46 181 8.39%
2 Citi 15,145.16 114 6.14%
3 JPMorgan 12,957.39 88 5.25%
4 Standard Chartered Bank 10,112.16 101 4.10%
5 Bank of China 9,370.02 117 3.80%

Asian polls & awards